Microfluidics-derived hierarchical microparticles for the delivery of dienogest for localized endometriosis therapy
Microfluidics-fabricated hierarchical microparticles encapsulate dienogest-loaded microspheres to achieve sustained release and cell adhesion for localized endometriosis treatment, demonstrating anti-inflammatory and anti-angiogenic effects in vivo.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (55)
- A mouse model of endometriosis that displays vaginal, colon, cutaneous, and bladder sensory comorbidities via openalex
- Antiangiogenesis therapy for endometriosis via openalex
- Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model via openalex
- Endometriosis via openalex
- Endometriosis: A Disease with Few Direct Treatment Options via openalex
- Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis via openalex
- Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells via openalex
- Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs via openalex
- Novel Medicine for Endometriosis and Its Therapeutic Effect in a Mouse Model via openalex
- The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study via openalex
- The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval via openalex
- Update on endometriosis pathogenesis via openalex
- Use of dienogest in endometriosis: a narrative literature review and expert commentary via openalex
- W2921649378 via openalex
- W2970083543 via openalex
- W2996266725 via openalex
- W2999841188 via openalex
- W3016334905 via openalex
- W3043172017 via openalex
- W3048131598 via openalex
- W3134885188 via openalex
- W3153128705 via openalex
- W3175662601 via openalex
- W3180804871 via openalex
- W3196168773 via openalex
- W3197003023 via openalex
- W4200355601 via openalex
- W4206619128 via openalex
- W4210481130 via openalex
- W4211127517 via openalex
- W4229377134 via openalex
- W4234160457 via openalex
- W4283390809 via openalex
- W4286697968 via openalex
- W4306918464 via openalex
- W4311573126 via openalex
- W4321602234 via openalex
- W4327714853 via openalex
- W4366240179 via openalex
- W4385851713 via openalex
- W6736467252 via openalex
- W6805488865 via openalex
- W6806908988 via openalex
- W1965699572 via openalex
- W1998380582 via openalex
- W2040932988 via openalex
- W2293579526 via openalex
- W2326952233 via openalex
- W2548144690 via openalex
- W2617378503 via openalex
- W2740636098 via openalex
- W2808449407 via openalex
- W2809514115 via openalex
- W2908838385 via openalex
- W2908903548 via openalex
Cited by (5)
- NRF2 signalling in endometriosis: A hormone-independent axis for fertility-preserving therapeutic innovation 2026
- Nanomaterial Platforms for Endometriosis: A Systematic Review 2026
- What are the most significant challenges in understanding and managing endometriosis today? 2025
- Enhanced peroperative imaging of endometriosis and peritoneal carcinomatosis 2024
- Emerging strategies for the treatment of endometriosis 2024
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-15T06:06:57.883625+00:00